Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 7/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30006992 | 1.00 | CTSA (0.35) | CTSAGABRA5CYP2C9MAPK14ROCK2 | |
| SCHEMBL23958639 | 1.00 | CTSA (0.35) | CTSAGABRA5CYP2C9MAPK14ROCK2 | |
| SCHEMBL25275834 | 0.93 | CFTR (0.36) | CTSACYP2C9MAPK14ROCK2ROCK1 | |
| SCHEMBL25687253 | 0.93 | CFTR (0.36) | CTSACYP2C9MAPK14ROCK2ROCK1 | |
| SCHEMBL28909166 | 0.91 | MAPT (0.35) | CTSACYP2C9MAPK14ROCK2ROCK1 | |
| SCHEMBL30007107 | 0.91 | MAPT (0.35) | CTSACYP2C9MAPK14ROCK2ROCK1 | |
| SCHEMBL25687257 | 0.91 | MAPT (0.35) | CTSACYP2C9MAPK14ROCK2ROCK1 | |
| SCHEMBL23958892 | 0.90 | CTSA (0.35) | CTSAGABRA5CYP2C9MAPK14ROCK2 | |
| SCHEMBL30007118 | 0.90 | CTSA (0.35) | CTSAGABRA5CYP2C9MAPK14ROCK2 | |
| SCHEMBL25687368 | 0.90 | CTSA (0.35) | CTSAGABRA5CYP2C9MAPK14ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| CN-115461336-A | RSV inhibiting 3-substituted quinoline and cinnoline derivatives | 爱尔兰詹森科学公司 | 2022-12-09 | — | — | CN | disclosed |
| WO-2021214136-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | ACE2, SIRT7, ACE | CTSA 473/4885GABRA5 3534/4885CYP2C9 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.